What medication has fewer side effects: semaglutide or tirzepatide?

In cross-trial data, tirzepatide tends to show lower rates of nausea and vomiting than semaglutide – despite producing more weight loss. But in the one head-to-head trial that compared them directly, SURMOUNT-5, tolerability was broadly similar. So the honest answer is nuanced: tirzepatide may have a slight edge on the most common side effects, but both share the same GI profile, and your individual experience matters more than the averages. Here’s the full comparison.

Key takeaways

• Both semaglutide and tirzepatide cause the same types of GI side effects – mostly nausea, diarrhea, and vomiting
• Cross-trial data suggests tirzepatide has lower nausea (24-33% vs 40-44%) and vomiting rates
• The head-to-head SURMOUNT-5 trial found broadly comparable tolerability between the two
• Tirzepatide’s GIP receptor component may buffer some GI effects, though this isn’t settled
• Side effects for both peak in the first 1-2 weeks of each dose, then ease over 2-4 weeks
• Slow dose titration is the single biggest factor in keeping side effects manageable

Which has fewer side effects, semaglutide or tirzepatide?

This is the question most people actually want answered, so here’s the direct version. On paper, tirzepatide (Mounjaro, Zepbound) tends to show lower rates of the most common side effects – nausea and vomiting – than semaglutide (Ozempic, Wegovy). That’s the surprising part, because tirzepatide is also the more potent drug for weight loss.

But two important caveats keep this from being a clean win. First, most of those numbers come from comparing separate trials, not head-to-head testing. Second, the one trial that did compare them directly found tolerability was broadly similar. So tirzepatide may have a modest edge, but “fewer side effects” is a tendency, not a guarantee – and the type of side effects is identical either way.

Compare the options: tirzepatide · semaglutide · weight loss prescriptions

Side effect rates: semaglutide vs tirzepatide

Here’s where the cross-trial numbers point. Both drugs cause the same gastrointestinal side effects, but the reported frequencies differ:

Across every category, tirzepatide’s reported rates come in lower. The gap is most striking for nausea and vomiting – the two side effects people find hardest to tolerate. For practical tips on managing these, see why GLP-1 medications cause nausea.

Read these numbers with care, though. They come largely from different trials with different patient populations, not a single study pitting the drugs against each other. Cross-trial comparisons can mislead.

What the SURMOUNT-5 head-to-head trial found

SURMOUNT-5 is the trial that matters most here, because it directly compared tirzepatide and semaglutide in the same study. On weight loss, tirzepatide won clearly – about 20.2% versus 13.7% for semaglutide. For a deeper look at that result, see how to switch from Zepbound to Wegovy.

On side effects, the result was more even. SURMOUNT-5 reported broadly comparable tolerability between the two drugs – both caused mostly mild-to-moderate GI symptoms, and the difference in discontinuation wasn’t dramatic. In other words, when tested directly, tirzepatide didn’t show the large tolerability advantage the cross-trial numbers might suggest.

The takeaway: tirzepatide delivers more weight loss without more side effects, which is its real edge. “Fewer” side effects is less certain than “not more.”

Why might tirzepatide cause fewer GI side effects?

There’s a plausible biological reason tirzepatide might be gentler on the gut despite being stronger. Tirzepatide activates two receptors – GLP-1 and GIP – while semaglutide activates only GLP-1.

The leading theory is that the GIP component has a buffering effect on nausea and other GI symptoms. GIP signaling may partly counteract the gut effects that drive nausea, softening them even as the combined action produces more weight loss. This is still being studied and isn’t fully settled, but it’s the best current explanation for how one drug can be both more effective and, on average, no harder to tolerate.

When do side effects happen, and do they last?

For both medications, the pattern is the same and worth understanding, because it’s reassuring. Side effects:

• Peak in the first 1-2 weeks after starting or increasing a dose
• Then ease over the following 2-4 weeks as your body adapts
• Are usually mild to moderate, not severe
• Are worst during titration, not at steady maintenance doses

This is exactly why both drugs use slow, stepwise dose escalation. Rushing it is the main thing that makes side effects worse. For how the timing works, see how long to stay on each GLP-1 dose before increasing.

How to minimize side effects on either medication

Whichever drug you take, the same habits reduce side effects:

• Titrate slowly – never rush to a higher dose; staying longer at a tolerable dose is fine
• Eat smaller meals – large meals worsen nausea when digestion is already slowed
• Avoid greasy, rich foods – they’re harder to tolerate during the adjustment period
• Stay hydrated – important especially if you have any diarrhea or vomiting
• Tell your provider early – if side effects are rough, a slower titration often fixes it

The drug you can actually stay on consistently matters far more than a few percentage points of difference on a side-effect chart.

The bottom line: semaglutide or tirzepatide for fewer side effects

Tirzepatide tends to show lower nausea and vomiting rates than semaglutide in cross-trial data, and it does this while producing more weight loss – a genuine advantage. But the head-to-head SURMOUNT-5 trial found tolerability broadly comparable, so the real story is that tirzepatide gives more results without more side effects, rather than dramatically fewer. Both share the same GI profile, both ease after the first few weeks, and both depend on slow titration. The best choice comes down to your goals, cost, and how your own body responds.

Not sure which medication fits you? Talk to a Heally provider about semaglutide, tirzepatide, and which is the better match for your goals and tolerance.

FAQ

Does semaglutide or tirzepatide have fewer side effects?

Cross-trial data suggests tirzepatide has lower nausea and vomiting rates than semaglutide, despite producing more weight loss. However, the head-to-head SURMOUNT-5 trial found broadly comparable tolerability. Both cause the same types of GI side effects.

Why does tirzepatide cause less nausea than semaglutide?

The leading theory is that tirzepatide’s GIP receptor activity buffers some gut side effects. Semaglutide acts only on GLP-1 receptors, while tirzepatide acts on both GLP-1 and GIP, which may soften nausea even though it produces more weight loss. This isn’t fully settled.

What are the most common side effects of semaglutide and tirzepatide?

Both cause mainly gastrointestinal side effects: nausea, diarrhea, vomiting, and constipation. These are usually mild to moderate, peak in the first 1-2 weeks of each dose, and ease over the following 2-4 weeks as the body adjusts.

Do side effects mean the medication is working?

Not necessarily. Side effects reflect how your body is adjusting to the drug’s effect on digestion, not how much weight you’ll lose. Some people have strong results with few side effects, and vice versa. Don’t judge effectiveness by how sick you feel.

How can I reduce side effects on semaglutide or tirzepatide?

Titrate slowly, eat smaller and lower-fat meals, stay hydrated, and tell your provider early if side effects are rough – a slower dose increase usually helps. The medication you can take consistently matters more than small differences in side-effect rates.

Sources

1. Aronne LJ, et al. “Tirzepatide vs Semaglutide Once Weekly for Weight Loss” (SURMOUNT-5). New England Journal of Medicine, 2025.
2. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1). New England Journal of Medicine, 2022.
3. Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1). New England Journal of Medicine, 2021.
4. FDA. Labels for Wegovy, Ozempic, Zepbound, and Mounjaro.

This article is for educational purposes only and is not a substitute for professional medical advice. Both semaglutide and tirzepatide carry an FDA boxed warning about the potential risk of thyroid C-cell tumors – do not use them if you or a family member has a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Always consult a qualified healthcare provider before starting or changing any treatment.